(Total Views: 207)
Posted On: 04/01/2021 5:07:27 PM
Post# of 26
NetworkNewsBreaks – Healthtech Solutions Inc. (HLTT) Announces Plans to Acquire Precision Oncology Company
Healthtech Solutions (OTC: HLTT) has signed a contract to acquire a wholly owned subsidiary, Healthtech Oncology Inc., which will subsequently own a 100% interest in Varian Biopharmaceuticals Inc., a precision oncology company. Varian Bio is developing novel therapeutics for the treatment of cancer, including a proprietary atypical protein kinase C iota (“aPKCi”) inhibitor. Varian Bio’ has two lead drug candidates: VAR-101 (“VAR-101”) and VAR-102 (“VAR-102”); both drug candidates are in the pre-clinical research stage of development. HLTT’s investment in Varian aligns with its commitment to acquire and invest in cutting-edge healthcare technological companies. Precision oncology, which is when researchers and health care professionals utilize DNA testing to identify genetic mutations of unique tumors, may provide more targeted treatment recommendations designed to fight specific tumor types. In the announcement, Varian Bio noted that it has the support of leading oncology physicians and scientific institutions both in the United States and globally. “Varian Bio is at the leading edge of cancer treatment technology and it is an honor to have them join our portfolio,” said Healthtech Solutions chairman and CEO David Rubin in the press release. “The fact that they are developing therapies to target difficult-to-treat cancers such as pancreatic cancer demonstrates just how innovative their team is. Precision oncology is an exciting field and we’re thrilled to be a part of it.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Healthtech Solutions (OTC: HLTT) has signed a contract to acquire a wholly owned subsidiary, Healthtech Oncology Inc., which will subsequently own a 100% interest in Varian Biopharmaceuticals Inc., a precision oncology company. Varian Bio is developing novel therapeutics for the treatment of cancer, including a proprietary atypical protein kinase C iota (“aPKCi”) inhibitor. Varian Bio’ has two lead drug candidates: VAR-101 (“VAR-101”) and VAR-102 (“VAR-102”); both drug candidates are in the pre-clinical research stage of development. HLTT’s investment in Varian aligns with its commitment to acquire and invest in cutting-edge healthcare technological companies. Precision oncology, which is when researchers and health care professionals utilize DNA testing to identify genetic mutations of unique tumors, may provide more targeted treatment recommendations designed to fight specific tumor types. In the announcement, Varian Bio noted that it has the support of leading oncology physicians and scientific institutions both in the United States and globally. “Varian Bio is at the leading edge of cancer treatment technology and it is an honor to have them join our portfolio,” said Healthtech Solutions chairman and CEO David Rubin in the press release. “The fact that they are developing therapies to target difficult-to-treat cancers such as pancreatic cancer demonstrates just how innovative their team is. Precision oncology is an exciting field and we’re thrilled to be a part of it.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
